1. Scrip

Divest, Refocus, Transition: Multinationals Embark On Uncharted Path In China

 
• By Brian Yang

Facing unprecedented pricing pressures in China, multinationals are embarking on a major shift away from mature products to focus more on innovative drugs, but there are major challenges linked to the transition that won’t be easy to navigate, notes a new report.

airport runway under the sun as background
MNCs Embark On Uncharted Path In China • Source: Shutterstock

After years of pondering, now comes concrete action.

Amid unprecedented pricing pressures in China, pharma multinationals operating in the country are transitioning to focus more on innovative new drugs rather than relying on

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia